24.04
-0.82 (-3.30%)
| Previous Close | 24.86 |
| Open | 24.99 |
| Volume | 433,209 |
| Avg. Volume (3M) | 358,711 |
| Market Cap | 1,157,479,168 |
| Price / Earnings (Forward) | 454.55 |
| Price / Sales | 10.52 |
| Price / Book | 3.03 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -11.86% |
| Operating Margin (TTM) | -5.09% |
| Diluted EPS (TTM) | -0.190 |
| Quarterly Revenue Growth (YOY) | 29.90% |
| Total Debt/Equity (MRQ) | 7.64% |
| Current Ratio (MRQ) | 4.73 |
| Operating Cash Flow (TTM) | 14.63 M |
| Levered Free Cash Flow (TTM) | 39.10 M |
| Return on Assets (TTM) | -0.79% |
| Return on Equity (TTM) | -2.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | BioLife Solutions, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -1.0 |
| Average | 0.50 |
|
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 2.84% |
| % Held by Institutions | 100.53% |
| 52 Weeks Range | ||
| Median | 32.00 (33.11%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 29 Dec 2025 | 32.00 (33.11%) | Buy | 25.12 |
| 24 Nov 2025 | 32.00 (33.11%) | Buy | 26.35 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2025 Unaudited Revenue from Continuing Operations |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |